Company Spotlight: Healthcare & Pharmaceuticals

Pfizer Will Reward Shareholders With Zoetis Spin-Off

At the beginning of 2013, I selected pharmaceutical giant Pfizer (PFE) as one of my top ten stock picks…

From Seeking Alpha | 8 hours ago

Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff

Eli Lilly and Company (LLY) is heading straight for a patent cliff. Zyprexa lost patent protection in…

From Seeking Alpha | 19 hours ago

Vical Has A Deep Bench And Near-Term Catalysts

In my previous biotechnology industry article, A Journey To Add Biotech To The Portfolio, I investigated…

From Seeking Alpha | 21 hours ago

Exelixis Prepares For ASCO 2013, Stock Stays Rangebound

One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is…

From Seeking Alpha | 22 hours ago

Successful Capital Raise, Data For Lead Candidate, And Small Float Are Opportunitites For Stemline

By Ivan DeryuginStemline Therapeutics (STML) completed its IPO in January of this year, (the company…

From Seeking Alpha | 1 day ago

All Amarin Eyes On Sunday's Prescription Data

There is a war on between bulls and bears for the fate of biotech startup Amarin (AMRN). The next piece…

From Seeking Alpha | 1 day ago

Acadia: Multiple Data Points Suggest Further Upside In The Stock

Acadia Pharmaceuticals (ACAD) has to be one of the top performing stocks over the past year with a chart…

From Seeking Alpha | 1 day ago

Actavis Buys Warner Chilcott, Upside Seems Limited

On May 21, 2013, Actavis (ACT) announced that it would acquire Warner Chilcott (WCRX) for $20.08 per…

From Seeking Alpha | 1 day ago

2 Healthcare Companies With Recent Intensive Insider Buying

The healthcare sector has been the best-performing sector YTD with a gain of 22.3%. (click to enlarge)…

From Seeking Alpha | 1 day ago

United Therapeutics: A Growth Stock With Good Products And A Promising Pipeline

United Therapeutics (UTHR) is a biopharmaceutical company which develops and markets products for patients…

From Seeking Alpha | 1 day ago

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013

With a potential U.S. market for Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD)…

From Seeking Alpha | 1 day ago

Amarin Stays Rangebound, Prescriptions Stagnate

Amarin Corporation (NASDAQ: AMRN) has been struggling a lot lately as retail channel prescription data…

From Seeking Alpha | 1 day ago

Vivus Heats Up, Shorts Discouraged On Possible Bidding War

Vivus (NASDAQ: VVUS) has been seeing relatively modest growth in Qsymia (phentermine and topiramate…

From Seeking Alpha | 1 day ago

Dividend Growth Gem Medtronic Is A Cash Cow

Dividend Growth Newsletter holding Medtronic (MDT) reported wonderful fourth quarter results. Revenue…

From Seeking Alpha | 1 day ago

Amgen: Financial Analysis And Valuation

Overview Amgen, Inc. (AMGN) incorporated in 1980 is a global biotechnology company that discovers, develops,…

From Seeking Alpha | 1 day ago

Arena - Good Sales, Bad Sales, Long And Short

When the discussion turns to Arena Pharmaceuticals (ARNA) there is no shortage of opinion, passion,…

From Seeking Alpha | 1 day ago

Actavis To Increase Operational Synergies By Acquiring Warner

The pharmaceutical industry is one of the biggest industries in the world. Currently the global pharmaceutical…

From Seeking Alpha | 1 day ago

Pfizer Has Potential To Grow Despite Decreasing Sales

Pfizer (PFE) is the world's largest research-based pharmaceutical company. It discovers, manufactures…

From Seeking Alpha | 1 day ago

First Manhattan Still Playing Hardball With Vivus

First Manhattan, an investor with about a 10% stake in Vivus (VVUS), has now taken the step of increasing…

From Seeking Alpha | 2 days ago

Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy

The annual conference of The American Society of Clinical Oncology (ASCO) is currently less than a few…

From Seeking Alpha | 2 days ago

Follow The 'Smart Money' And Buy Johnson & Johnson In The Next Pullback

Shares of Johnson & Johnson (JNJ) have been in a solid uptrend throughout 2013. As shown in the…

From Seeking Alpha | 2 days ago

Why Merck Shares Are Cheap And Could Rise To $60

While many stocks are trading near 52-week highs or at stretched valuations, investors who selectively…

From Seeking Alpha | 2 days ago

Arena Is Still A Great Short

At the recent Bank of America Merrill Lynch 2013 Health Care Conference, Craig Audet Ph.D. gave an overview…

From Seeking Alpha | 2 days ago

Expanding Use Of Alexion's Specialty Drug Soliris Offers Upside

Ultra rare diseases have become big business for both pharmaceutical and biotechnology companies, such…

From Seeking Alpha | 2 days ago

Arena Buyout More 'Highly Probable' Than MannKind

I was compelled to compare the buyout prospect of Arena Pharmaceuticals (ARNA) with MannKind Corporation…

From Seeking Alpha | 2 days ago

Another Look At Marketing Vs. R&D In Pharma

FiercePharma has some good figures to back up my posts the other day on R&D spending versus marketing.…

From Seeking Alpha | 2 days ago

Thoratec, A Bio Stock With Good Potential And Products

Thoratec Corporation (THOR) is a market leader in developing mechanical circulatory support (MCS) for…

From Seeking Alpha | 2 days ago

Abbott Laboratories: Undervalued Potential

A substantial recovery perspective has factored into the perception regarding the pharmaceutical industry,…

From Seeking Alpha | 2 days ago

Zalicus Awaiting Data On Potential New Pain Medication

Zalicus (NASADQ:ZLCS) will have data in the second half of this year that will provide important insights…

From Seeking Alpha | 2 days ago

MannKind's Afrezza And The Oramed Threat

My last article concerning MannKind Corp. (MNKD) was a discussion of how its Afrezza will succeed where…

From Seeking Alpha | 2 days ago